Autologous tumor cell vaccines do not exacerbate DLI-induced GVHD after NST.

(A) Cured animals are mixed hematopoietic chimeras. Peripheral blood from animals cured of 4T1 by surgery, NST, DLI, and vaccine was obtained 6 months after DLI and vaccine administration and stained with FITC-conjugated antibody against Ly9.1, which is specific for host BALB/c lymphocytes, and PE-conjugated antibodies against CD4 and CD8. Dual-color flow cytometry from a representative animal is shown. (B-C) Effects on graft-versus-host disease (Table 1). (B) Graded doses of spleen cells (from 0 to 60 million) from BALB/c-sensitized B10.D2 donors were administered, with or without 4T1/B78H1–GM-CSF vaccine, to groups of 9 to 11 BALB/c mice that had received NST (as described in the legend to Figure 1) 2 weeks earlier. (B) Twelve weeks after spleen cell infusion, donor T-cell chimerism was measured by staining splenocytes of recipients (n = 4-6 per group) with FITC-conjugated antibody against Ly9.1 (host) and PE-conjugated antibodies against CD4 and CD8. ○ indicates individual vaccinated animals; ●, individual nonvaccinated animals. (C) C.B17-scid mice (n = 5 per group) received 200 cGy TBI on day −1 and graded doses (from 0 to 100 million) of unprimed B10.D2 spleen cells on day 0, with or without 4T1/B78H1–GM-CSF vaccine on day 3. Mice were weighed on day −1 and day 40, and percentage of weight change from baseline is plotted as a function of spleen cell dose. ░ indicates vaccinated animals; ▪, nonvaccinated animals.